197 related articles for article (PubMed ID: 12176640)
1. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes.
Sundberg AK; Smith LD; Somerville KT; Cox R; Sherbotie JR
Transplant Proc; 2002 Aug; 34(5):1951-2. PubMed ID: 12176640
[No Abstract] [Full Text] [Related]
2. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
3. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
[No Abstract] [Full Text] [Related]
4. Clinical study of FK 506 in renal transplant recipients.
Youhua Z; Zhinlian M; Liming W
Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
[No Abstract] [Full Text] [Related]
5. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
[No Abstract] [Full Text] [Related]
7. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection.
Boratyńska M; Banasik M; Patrzałek D; Klinger M
Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290
[TBL] [Abstract][Full Text] [Related]
8. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
9. Steroid withdrawal in renal transplant recipients.
Oppenheimer F
Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
[No Abstract] [Full Text] [Related]
10. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients.
Citterio F; Rigotti P; Scatà MC; Romagnoli J; Baldan N; Marchini F; Castagneto M
Transplant Proc; 2002 Aug; 34(5):1707-8. PubMed ID: 12176545
[No Abstract] [Full Text] [Related]
11. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
Yu L; Wang Y; Fu SJ; Cheng XJ
Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
[No Abstract] [Full Text] [Related]
12. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
13. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients.
Colak T; Karakayali H; Yagmurdur MC; Moray G
Transplant Proc; 2002 Sep; 34(6):2081-2. PubMed ID: 12270321
[No Abstract] [Full Text] [Related]
14. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil.
Sola E; Alférez MJ; Cabello M; Burgos D; González Molina M
Transplant Proc; 2002 Aug; 34(5):1689-90. PubMed ID: 12176537
[No Abstract] [Full Text] [Related]
15. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
[No Abstract] [Full Text] [Related]
16. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy.
Wayman MR; Oniscu GC; Forsythe JL; Whitworth CE
Transplant Proc; 2002 Aug; 34(5):1663-5. PubMed ID: 12176526
[No Abstract] [Full Text] [Related]
17. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
[No Abstract] [Full Text] [Related]
18. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
Forsythe J
Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
[No Abstract] [Full Text] [Related]
19. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation.
Ciancio G; Burke G; Viciana A; Ruiz P; Roth D; Khan TF; Montane B; Strauss J; Miller J
Transplant Proc; 1998 Jun; 30(4):1536-7. PubMed ID: 9636624
[No Abstract] [Full Text] [Related]
20. Cyclosporin conversion to CellCept in a cadaveric renal allograft recipient with hemolytic uremic syndrome.
Said T; al-Mousawi M; Samhan M; Lao M
Transplant Proc; 1999 Dec; 31(8):3295-7. PubMed ID: 10616482
[No Abstract] [Full Text] [Related]
[Next] [New Search]
